Table 1. Proportion of patients with multidrug-resistant tuberculosis who would have qualified for treatment with the short (9-month) regimen or with bedaquiline-containing regimen, 2005–2008*.
| Candidate regimen | Country, no. patients (%) |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Estonia, n = 24 | Latvia, n = 89 | Peru, n = 194 | Philippines, n = 386 | Russia, n = 96 | South Africa, n = 281 | South Korea, n = 96 | Taiwan, n = 40 | Thailand, n = 48 | Total, N = 1,254 | |
| Short† | 13 (54.2) | 42 (47.2) | 154 (79.4) | 357 (92.5) | 59 (61.5) | 195 (69.4) | 58 (60.4) | 31 (77.5) | 43 (89.6) | 952 (75.9) |
| BDQ‡ | 11 (45.8) | 47 (52.8) | 40 (20.6) | 29 (7.5) | 37 (38.5) | 86 (30.6) | 38 (39.6) | 9 (22.5) | 5 (10.4) | 302 (24.1) |
*Percentages show proportion of patients in cohort form each country who would be candidates for a particular regimen. BDQ, bedaquiline. †Candidates for short regimen were patients without baseline resistance to fluoroquinolones and second-line injectable drugs. ‡Candidates for BDQ-containing regimen were patients with baseline resistance to fluoroquinolones or second-line injectable drugs.